pharmaphorum5d
BMS' Opdivo stumbles in lung cancer, but could still maintain lead
The news was a major tonic for Merck, which is chasing close behind Opdivo with its rival PD-1 drug Keytruda (pemtruzumab) across a number of cancer types. Opdivo has established a clear lead so ...
Zacks Investment Research on MSN4d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Pharmaceutical Technology on MSN4d
EC approves BMS’ Opdivo and Yervoy combo for HCC
The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...
GlobalData on MSN17d
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an Opdivo (nivolumab) and Yervoy (ipilimumab) combo as a first ...
Bristol Myers' Opdivo Plus Yervoy Combo Therapy Secures European Approval For Untreated Liver Cancer Patients
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
2BMY : Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a decision expected by June 2025.
Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...
Nasdaq4d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult ...